Full Archive
Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy
Frontiers in Oncology 2026 August 13 [Link] Hongmei Li, Kunzhong Zhou, Ruiting Xu, Weifang Wang, Tingting Song, Yonghong Zhou, Jing Ren, Zhiyong Wang, Yiteng Liang, Yilin Chen, Saurav Poudel, Junxuan Yu, Rui Lin, Ke Yin, Shengjie Yang, Li Zhuang Abstract Malignant pleural mesothelioma (MPM) exhibits substantial molecular and cell-state heterogeneity, together with marked spatial variation…
Read MoreThonzonium bromide suppresses malignant phenotypes of pleural mesothelioma cells in association with reduced KAP1 Ser473 phosphorylation
Tissue & Cell 2026 August 22 [Link] Dan Song, Jintao He, Qianwen Du, Shaoyang Huang, Wenbing Huang, Zhengliang Li, Zifeng Ruan, Xingguo Liu, Jing Zhang, Wei Xiong Abstract Objective: Pleural mesothelioma (PM) is an aggressive thoracic malignancy with limited therapeutic options. This study investigated the biological role of KAP1 in PM and explored the relationship…
Read MoreAsbestos mineral fibre exposure significantly affects volatile organic compound profiles of mesothelial cell lines in vitro
Scientific Reports 2026 August 29 [Link] Sam Bonsall, Theo Issitt, Nick Peake, Mari Herigstad, Jason Webber, Sarah Haywood-Small Abstract Malignant mesothelioma (MM) is a rare cancer caused by exposure to asbestos, this condition continues to represent a significant diagnostic and therapeutic challenge. Due to the long disease latency, non-invasive diagnostic modalities such as breath analysis…
Read MorePrognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis
Cancers 2026 August 11 [Link] Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz Abstract Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO…
Read MoreSex-Specific Patterns of Asbestos Exposure and Prognostic Biomarkers in Surgically Treated Pleural Mesothelioma: A Retrospective Cohort Study
Cancers 2026 August 14 [Link] Nicolas Pinzon, Shubham Gulati, Andrew Del Re, Emanuela Taioli, Raja Flores, Andrea S Wolf, Stephanie Tuminello Abstract Background/objectives: Sex-based differences in asbestos exposure and tumor biology in pleural mesothelioma (PM) remain incompletely characterized. As an expert tertiary center, we sought to systematically characterize asbestos exposure by sex and assess biomarker…
Read MorePrognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis
Annals of Surgical Oncology 2026 August 25 [Link] Jan Philipp Ramspott, Anna Kolmhofer, Ibrahim Büdeyri, Michael Weitzendorfer, Stephan Regenbogen, Lukas Schabl-Cayron, Philipp Schredl, Alexander D Bungert, Klaus Emmanuel, Dino Bekric, Jaroslav Presl, Andreas Pascher, Daniel Neureiter, Tarkan Jäger Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive disease in which cytoreductive surgery…
Read MoreIdentification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy
Discover Oncology 2026 July 25 [Link] Jing Ding, Xuefeng Huang, Wenxiu Yao, Tongyu Lin Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with increasing incidence, high mortality, and limited treatment options. Disulfidptosis, a newly identified form of regulated cell death, may play an important role in cancer, but its relevance in PM…
Read MoreHaemophagocytic Lymphohistiocytosis Following Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma: A Case Report
Cureus 2026 July 16 [Link] Cho May Than, Maung Moe, Ye Win, Kyaw Maung Abstract Haemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal hyperinflammatory syndrome caused by dysregulated immune activation. With the increasing use of immune checkpoint inhibitors (ICIs), HLH has emerged as an uncommon but serious immune-related adverse event. An 84-year-old woman with…
Read MoreADRB2 modulates asbestos-induced pleural mesothelioma progression by influencing IL-17/NF-κB-related inflammatory signalling: An integrated network toxicology, multi-omics and experimental study
Chemico-Biological Interactions 2026 October 1 [Link] Shaoyang Huang, Dandan Gu, Jintao He, Guangsheng Hou, Jundong Wang, Zhengliang Li, Min Yu, Jiangyan Li, Wei Xiong Abstract Pleural mesothelioma (PM) is a highly aggressive asbestos-related malignancy with a poor prognosis and limited early diagnostic options. In this study, network toxicology and integrated multi-omics analyses were used to…
Read MoreRetrospective cohort study on prognostic factors of malignant pleural effusion secondary to pleural mesothelioma
Journal of Thoracic Disease 2026 July 31 [Link] Xin Qiao, Jing-Jing Zhang, Bin Liu, Jian-Wen Qin Abstract Background: Malignant pleural effusion (MPE) frequently complicates pleural mesothelioma; however, prognostic determinants for this condition, particularly pleural fluid biomarkers, have yet to be comprehensively characterized. This study sought to assess the prognostic utility of clinical profiles and laboratory…
Read More
Skip to content